AJ Bergmann
Chief Financial Officer at Capricor Therapeutics, Inc - Los Angeles, California, United States
AJ Bergmann's Colleagues at Capricor Therapeutics, Inc
Tristin McGuffick
Associate Director of Technology Transfers, Project Management
AJ Bergmann's Contact Details
Capricor Therapeutics, Inc
AJ Bergmann's Company Details
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac cell therapy. CAP-1002 consists of cardiosphere-derived cells, or CDCs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system's activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are now focused on developing a precision-engineered exosome platform technology that can carry defined sets of effector molecules including nucleic acids which exert their effects through defined mechanisms of action. We have begun work on our expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases.